Advertisement

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

Chelsea C. Pinnix, Sarah A. Milgrom, Chan Yoon Cheah, Jillian R. Gunther, Ethan B. Ludmir, Christine F. Wogan, Loretta J. Nastoupil, Sattva S. Neelapu, Jason Westin, Hun J. Lee, Swaminathan P. Iyer, Raphael E. Steiner, Luis E. Fayad, Nathan H. Fowler, Michael L. Wang, Felipe Samaniego, Maria A. Rodriguez, Amy E. Rich, L. Jeffrey Medeiros and Bouthaina S. Dabaja

Article Information

Citation 
vol. 3 no. 9 1356-1367
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted November 26, 2018
  • Accepted March 8, 2019
  • Published online April 29, 2019.


Contributors 
  • Chelsea C. Pinnix, 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Sarah A. Milgrom, 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Chan Yoon Cheah, 2Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia;3Department of Haematology, Pathwest Laboratory Medicine, Nedlands, WA, Australia;4Medical School, University of Western Australia, Crawley, WA, Australia;
  • Jillian R. Gunther, 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Ethan B. Ludmir, 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Christine F. Wogan, 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Loretta J. Nastoupil, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Sattva S. Neelapu, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Jason Westin, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Hun J. Lee, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Swaminathan P. Iyer, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Raphael E. Steiner, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Luis E. Fayad, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Nathan H. Fowler, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Michael L. Wang, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Felipe Samaniego, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Maria A. Rodriguez, 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Amy E. Rich, 6Orlando Regional Medical Center, Orlando, FL; and
  • L. Jeffrey Medeiros, 7Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Bouthaina S. Dabaja, 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output